Entecavir (Entecavir) Patent Expiration, LOE Window & CMS Spending

Entecavir (Entecavir) by Multi-Source Generic Manufacturers: Multi-Source Generic Molecule, 8 AB generics, $31.7M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMulti-Source Generic Manufacturers
FDA Application & PathwayReconciled (ANDA)
Exclusivity / Cliff HorizonMulti-Source Generic Molecule
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors8
2024 CMS Total Public Spend$31.7M
2024 Medicare Part D Spend$27.1M
2024 Medicaid Spend$4.6M
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 284.0% 2-yr change)